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S U M M A R Y
In the last few years, chikungunya has become a major problem in Southeast Asia, with large numbers of
cases being reported in Singapore, Malaysia, and Thailand. Much of the current epidemic of chikungunya
in Southeast Asia is being driven by the emergence of a strain of chikungunya virus that originated in
Africa and spread to islands in the Indian Ocean, as well as to India and Sri Lanka, and then onwards to
Southeast Asia. There is currently no speciﬁc treatment for chikungunya and no vaccine is available for
this disease. This review seeks to provide a short update on the reemergence of chikungunya in Southeast
Asia and the prospects for control of this disease.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Chikungunya virus (CHIKV) is the causative agent of chikun-
gunya fever, which is a global public health problem.1–3 The
disease was ﬁrst formally described in 1955 following an outbreak
in Tanzania, Africa in 1952,4 and the virus was ﬁrst isolated shortly
thereafter.5 CHIKV is a virus of the genus Alphavirus belonging to
the family Togaviridae, and the genome consists of a linear,
positive-sense single-stranded RNA molecule of approximately
11.8 kb, which encodes for four non-structural proteins (nsP1–
nsP4), three structural proteins (C, E1, and E2), and two proteins of
ill-deﬁned function (E3 and 6K).
Three distinct lineages of CHIKV are believed to be circulating –
two from Africa (West African and East Central and South African)
and an Asian genotype.6 The Asian lineage is believed to have
diverged from the East Central and South African (ECSA) lineage
either between 50 and 310 years ago7 or between 61 and 124 years
ago.8
In nature, CHIKV is maintained in two primary transmission
cycles.6 In Asia the virus is believed to be largely maintained in a
mosquito–human–mosquito cycle, with the urban anthropophilic* Corresponding author. Tel.: +66 2 800 3624-8; fax: +66 2 441 9906..
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virus is believed to be maintained primarily in a sylvatic cycle
involving wild, non-human primates, such as macaques, and
forest-dwelling Aedes mosquito species such as Aedes furcifer, Aedes
taylori, Aedes luteocephalus, Aedes africanus, and Aedes neoafrica-
nus.6
Classically, CHIKV infections are characterized by high fever,
nausea, rash, and severe arthralgia, and symptomatically, chikun-
gunya fever can be difﬁcult to differentiate from dengue fever.9 The
association of CHIKV infection with severe joint pain is believed to
have been the origin of the name chikungunya, which derives from
the East African Makonde language and means ‘that which bends up’.
Several studies have implicated a more severe pathobiology in
recent years. In the 1963 outbreak in India, neurological and
hematological complications were reported for the ﬁrst time.10,11
More pertinently however, in a 2005/6 outbreak on La Re´union
Island in the Indian Ocean, chikungunya started to present with
very complicated clinico-pathological manifestations, primarily
associated with encephalopathy and hemorrhagic fever.12,13
Arthralgia persisted for months or years in joints, causing severe
pain, with the aged, particularly those suffering from diabetes,
alcoholic hepatopathy, or impaired renal functions, suffering the
most. This epidemic also marked the ﬁrst chikungunya deaths, as
well as the ﬁrst cases of peripartum mother-to-child transmis-
sion.14–16 Particularly signiﬁcant was the extent of this outbreak,ses. Published by Elsevier Ltd. All rights reserved.
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population.17
More recent outbreaks in India have been characterized by high
morbidity or extensive incapacitation. Again, neurological and
renal involvement was reported in the disease pathology,18–20 as
well as ophthalmic involvement, hypokalemic paralysis, hearing
loss, Guillain–Barre´ syndrome, and acute ﬂaccid paralysis.21–28
Signiﬁcant abnormalities in the cerebrospinal ﬂuid, raised hepatic
enzymes, and altered renal function have all been reported in large
numbers of patients in post-La Re´union outbreaks.6
As noted above, one of the most critical aspects of CHIKV
infection is the severe arthralgia that can persist for months or
years in joints,29 causing severe pain. Understanding this process is
one of the more urgent requirements in understanding the
pathology of CHIKV infections. The earliest work on understanding
the pathology of CHIKV infections came from studies in mice
deﬁcient for the type-1 interferon pathway.14 While this animal
model does not completely capture the pathology of human
infections, it was shown that after an initial round of replication in
the liver, CHIKV primarily targets muscle, joint, and skin
ﬁbroblasts. Markedly, dissemination of the virus to tissues in
the central nervous system was also observed, which mirrors the
neurological involvement seen in some cases of CHIKV infection. In
a study on non-human primates,30macrophages were identiﬁed as
a long-lasting reservoir of viral infection in monkeys, which is
believed to explain the long-lasting symptoms in humans. Further
studies in mice31 have implicated proinﬂammatory factors
released by alphavirus-infected macrophages as being critical
mediators of arthralgia/arthritis, which is consistent with studies
on human patients.29 A more recent study has shown that levels of
viremia during the acute phase determined the speciﬁc pattern of
pro-inﬂammatory cytokines and that high levels of interleukin-6
and granulocyte macrophage colony-stimulating factor were
associated with persistent arthralgia.32
The outbreak on La Re´union apparently marked a signiﬁcant
turning point in the pathobiology of chikungunya fever. Critically,
the virus became more transmissible by Aedes albopictus, and
possibly by A. aegypti as well. Examination of isolates from the La
Re´union outbreak pinpointed a single mutation, a change of
alanine to valine of amino acid 226 of the E1 protein (E1-A226 V) in
the ECSA lineage,33 which has been implicated as being the
causative factor,34 and it has been shown that this mutation was
responsible for the enhanced infectivity in both A. aegypti and A.
albopictus, although the reasons for this are less clear.34 Some
speculation has suggested that this mutation might reduce the
cholesterol dependence of the virus33 and might help in replication
and transmission of the virus. Less clear at this point is whether the
mutation is causatively associated with the changes in disease
pathology seen since the 2005/6 outbreak on La Re´union. However,
it is the ECSA lineage that has been driving the vast majority of the
outbreak in Southeast Asia.
2. The road to Southeast Asia
The origin of the progenitor ECSA CHIKV strain that has led to
the current outbreak sweeping across Southeast Asia remains open
to debate. While some authors propose that the progenitor strain
arose in the neighborhood of Uganda,8 other authors feel this is not
fully consistent with phylogenetic analyses and have proposed
that a common ancestral strain arose around the time of an
outbreak of chikungunya in Kenya in 2004.35 It is however possible
that the Ugandan-82 strain is the progenitor of the Kenyan 2004
isolates. This common ancestral strain of the ECSA lineage is
proposed to have been wild-type for the critical E1-A226 V
mutation,35 and was subsequently responsible for the outbreaks
on the Indian Ocean islands of Comoros and Seychelles in 2005,36with the outbreak being spread by A. aegypti mosquitoes.37 This
outbreak spread to the islands of La Re´union and Mauritius, where
early infections were characterized as wild-type for the E1-A226 V
mutation.38 On La Re´union and Mauritius however, the principal
mosquito vector species is A. albopictus, and it is believed that
adaptation to A. albopictus led to the emergence of an E1-226 V
strain of the ECSA lineage, and this lineage was predominantly
responsible for the massive outbreak on La Re´union during the
2005/2006 period.38
CHIKV subsequently spread to India, where it was responsible
for a massive outbreak between December 2005 and the end of
2008, with some 1.5 million affected cases. DNA sequence and
phylogenetic analysis however show that this outbreak did not
originate with the E1-226 V strain on La Re´union, as the early
infections in India from around 2006 were characterized as being
wild-type at E1-226,39,40 and comprehensive phylogenetic analy-
sis indicates that the Indian Ocean/La Re´union E1-226 V lineage
forms a separate cluster from the Indian (and subsequently
Southeast Asian) CHIKV strains.35
As noted, early reports from India characterized the CHIKV
strain responsible for the massive outbreak as being wild-type for
E1-A226 V and possibly arriving in India from East Africa or
Comoros,41 and it is believed that this was spread primarily by A.
aegypti mosquitoes.6 However, later infections (from 2007
onwards) were shown to originate from CHIKV carrying the E1-
226 V mutation,39,40 with transmission being driven by A.
albopictus.42 Remarkably, sequence analysis suggests that the
E1-226 V mutation in the Indian lineage CHIKV strains originated
independently from the event leading to the La Re´union E1-226 V
CHIKV strains in an example of convergent evolution.35,41 More
remarkable still, is that the 2006 and 2007 chikungunya outbreaks
in Cameroon and Gabon similarly likely arose from importation of
a wild-type strain of the ECSA lineage (also possibly from the 2004
Kenya chikungunya outbreak), which independently acquired the
E1-226 V mutation.41 In all cases it seems to be the adaptation to A.
albopictus that is associated with the emergence of this mutation.41
The outbreak of chikungunya in Italy in 2007 that caused
signiﬁcant concern in Europe,43 arose from the importation of
an Indian ECSA strain, through an individual who was asymptom-
atic upon arrival in Italy, but developed symptoms 2 days after his
arrival. Sequencing demonstrated the presence of the E1-226 V
mutation, and local transmission was facilitated by high levels of A.
albopictus in Italy at the time of arrival of the index patient.44
Sri Lanka experienced a signiﬁcant outbreak of chikungunya
starting from October 2006.45 Again, as was seen in both La
Re´union and India, early cases that arose predominantly in coastal
and urban setting towns were wild-type for E1-226, while later
cases (2008 onward) were predominantly in plantation areas and
were characterized as carrying the E1-226 V mutation.35 Again,
data suggest that the E1-226 V mutation was acquired locally and
that adaptation to A. albopictus was a signiﬁcant factor,35 although
at this point it would seem unwise to rule out multiple
importations from India, as chikungunya cases caused by ECSA
carrying the E1-226 V mutation are temporally linked between
India and Sri Lanka. Signiﬁcantly however, the Sri Lankan CHIKV
strains contain signature mutations characteristic of the prevalent
CHIKV strains present in Southeast Asia.35
3. Chikungunya in Southeast Asia
Chikungunya, or at least a disease strongly suggestive of
chikungunya, has historically been present in Southeast Asia since
the late 1700s,35,46 with the ﬁrst regional isolation of the virus
occurring in 1958 in Thailand.47 While chikungunya was common
in Southeast Asia in the late 1950s and 1960s, it was restricted to
sporadic outbreaks from the late 1960s until the second half of the
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outbreak that has swept across Southeast Asia, chikungunya was
caused by viruses belonging to the Asian lineage, which, as noted
earlier, is believed to have diverged from the ECSA lineage between
50 and 300 years ago.7,8 Interestingly, there are no data to suggest
that the Asian lineage CHIKV has been re-introduced back into
Africa. While the current outbreak in Southeast Asia results from
the ECSA lineage, it is believed that Asian lineage CHIKV still
circulates in Southeast Asia.35,46
3.1. Malaysia, Singapore, and Thailand
In the last 15 years, Malaysia has seen outbreaks of
chikungunya fever caused by both the Asian and the ECSA lineage.
An outbreak in 1998 in Klang in Selangor State (located some
30 km west of the capital of Kuala Lumpur), which affected 51
people,49 was the ﬁrst recorded outbreak of chikungunya in
Malaysia, although low levels of CHIKV seropositivity have been
recorded in the local population, suggesting a low level of
transmission of the virus before the ﬁrst outbreak.50 A second
outbreak of chikungunya was recorded between March and April
2006 in Bagan Panchor, Perak, which affected more than 200
people.51 While this second outbreak coincided with the peak of
the 2005/6 outbreak on La Re´union Island and with the start of the
Indian subcontinent outbreak, evidence showed that this Malay-
sian outbreak as well as the previous outbreak resulted from
transmission of the Asian lineage CHIKV.52 A third, limited
outbreak also occurred in Malaysia in December 2006 in Ipoh,
Perak, which was caused by importation of an ECSA strain from
India.53 A major, nationwide outbreak of chikungunya started in
April 2008 that spread to 14 out of 15 states and federal territories,
and sequence analysis showed that this outbreak was driven by
circulation of the E1-226 V mutation in the ECSA strain.52 The
association of the cases with primarily rural areas implicated
transmission by A. albopictus mosquitoes.52
Singapore, the small city state located at the southern end of the
Malay Peninsula, has frequently experienced imported cases of
chikungunya in the past, but these have not resulted in local
transmission of the virus.46 The ﬁrst cases of autochthonous
transmission of CHIKV were reported from January 14, 2008 until
February 21, 2008 in a localized outbreak that affected 13
patients.54 A second limited outbreak of two cases was reported
in May 2008, while a third case that only involved one patient was
reported in June 2008.54 Phylogenetic analysis determined that all
of the causative viruses were of the ECSA lineage, most likely of
Indian, Malaysian, and Sri Lankan origin, respectively.35 From July
2008 a major outbreak was reported with more than 1000 patients
affected,48 with transmission of both the wild-type ECSA (E1-
A226) and mutant (E1-226 V) being reported.35,46 Transmission of
the wild-type E1-A226 ECSA is believed to occur predominantly via
A. aegypti mosquitoes in an urban setting, while the mutant E1-
226 V is associated with more rural transmission by A. albopic-
tus.35,46 Phylogenetic analysis suggests that Sri Lankan, Singapor-
ean, and Malaysian CHIKVs all share common signature mutations,
indicative that they are closely phylogenetically related, although
the presence of other unique signatures suggests that microevolu-
tion of CHIKV occurred in both Sri Lanka and Singapore/Malaysia.35
Thailand has suffered several signiﬁcant outbreaks of chikun-
gunya since the ﬁrst reported case in 1960,47 and past outbreaks in
Thailand include those in the provinces of Prachinburi (1976),
Surin (1988), Khon Kaen (July 1991), Loei and Phayao (1993),
Nakhon Si Thammarat (July 1995), and Nong Khai (August 1995).
In the most recent outbreak in the southern provinces of Thailand
(2008/2009), some 22 000 cases of chikungunya were diagnosed in
the ﬁrst 5 months of 2009. The outbreaks prior to the current
outbreak were the result of circulation of the Asian lineage,7 whileevidence has shown that the current outbreak is the result of the
introduction of the ECSA lineage to Asia.55 The ﬁrst reported cases
in Thailand during the current outbreak were reported in October
2008 in the province of Narathiwat, one of the southern-most
provinces of Thailand, which is adjacent to the Malaysian state of
Kelantan. Sequence analysis showed that the virus belonged to the
ECSA lineage and had the E1-226 V mutation.55 Consistent with
other reports, A. albopictus was believed to be the primary
transmission vector, and CHIKV was isolated from ﬁeld-caught
A. albopictus in the area of the outbreak.56 From the initial outbreak
that was focused around ﬁve villages in Narathiwat, chikungunya
spread throughout much of Thailand, and by December 2009
chikungunya had been reported in 43 of the 75 provinces of
Thailand, with cases reported in central, northeastern, and
northern provinces in addition to its presence in the southern
provinces;57 more than 46 000 cases of chikungunya were
reported. The virus isolated from both early and late outbreak
cases grouped phylogenetically with the viruses from Singapore,
Malaysia, and Sri Lanka, although the presence of some unique
amino acid changes could indicate further evolution of the virus in
Thailand.57
3.2. The rest of Southeast Asia
Details on CHIKV infections in other countries in Southeast Asia
are scarce, with few if any detailed studies on CHIKV infections and
the lineage of the virus that causes the infections. The ﬁrst evidence
for the presence of CHIKV in Indonesia comes from a seroconver-
sion survey conducted in 197258 suggesting the widespread
presence of the virus in Indonesia. Outbreaks of chikungunya were
frequently recorded between 1982 and 1985 throughout
Indonesia, after which there was a period of some 16 years until
2001, when a series of 13 outbreaks were reported between
September 2001 and March 2003.59 To date, there is little
published work on the lineage of the virus responsible for the
early outbreaks, although given the timeframe it is highly likely
that these were a consequence of transmission of the Asian
genotype CHIKV. Analysis of cases of CHIKV infection imported to
Singapore in 2008 however, have shed some light on the current
situation in Indonesia, with CHIKV isolates clustering with both the
ECSA and Asian lineage being identiﬁed, suggesting that both
lineages are currently circulating.46 The ECSA Indonesian isolate
imported into Singapore clustered with Malaysian/Singapore/
Indian ECSA isolates from the recent outbreak, suggesting a
common origin.46 The Philippines similarly experienced scattered
occurrences of chikungunya between the mid 1950s and later
1960s.60,61 The infections in 1986 of three US Peace Corps
Volunteers stationed in the Philippines62 were the ﬁrst reported
cases of chikungunya in the Republic of the Philippines since the
late 1960s. With the exception of a single report describing an
outbreak of chikungunya in 1996,63 there is no information as to
the status of chikungunya in the Philippines. Similarly, we were
unable to ﬁnd formal published reports on the current status of
chikungunya in Vietnam, Cambodia, Laos, and Myanmar.
4. Vector control strategies: lessons from Singapore
In the absence of a vaccine (see below), efforts at controlling the
spread of chikungunya are primarily centered around vector
control strategies that seek to reduce potential breeding sites, kill
larvae through the action of larvicides such as temephos or Bacillus
larvicidal toxins,64 or reduce the numbers of adult mosquitoes
through space spraying using pyrethroids or organophosphates.
Singapore has a long history of vigorous vector control programs,
which include public awareness programs aimed at reducing
breeding sites for mosquitoes around the home.65 However, the
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controlling the emergence and spread of dengue, and the success of
this program led to a shift in emphasis from vector surveillance to
the early detection of cases of dengue coupled with emergency
vector control programs at identiﬁed outbreak clusters.65 In this
way the chikungunya outbreak was largely unanticipated, and only
with the appropriate identiﬁcation of A. albopictus as the primary
transmission vector were appropriate control measures put in
place to target the exophilic and exophagic A. albopictus mosquito.
These control measures effectively brought the outbreak under
control, and underscored the necessity of combining mosquito
control programs with comprehensive virological surveillance of
mosquito populations.66,67
5. The prospects for a chikungunya vaccine
Although the causative agent of chikungunya fever was
identiﬁed more than 50 years ago,5 and despite its continued
circulation in Africa and parts of Asia, there remains no
commercially available vaccine, possibly due to the sporadic and
limited nature of the outbreaks of this disease since the 1960s.
Interestingly however, the attempts to develop a CHIKV vaccine
can be traced back to about a decade after the virus was ﬁrst
isolated, when Harrison and colleagues compared the immuno-
genicities of formalin-inactivated CHIKV strain 168, an isolate from
the 1952–53 Tanzanian outbreak, prepared from different tissue
sources.68 They showed that an inactivated CHIKV produced from
green monkey kidney cells elicited the highest level of immune
response while showing no neurovirulence in mice. The vaccine
candidate also provided protection against lethal CHIKV challenge
in a mouse model system and against viremia in a monkey model
system.68 Based upon these results, this group of investigators
expanded their studies by applying a different method of
inactivation (Tween–ether extraction) to the same strain of the
virus69 or using the same formalin inactivation approach to a
different genotype of CHIKV, namely the Asian genotype strain
15561.70 Both of these vaccine candidates were shown to be
immunogenic and afforded protection to mice against three
heterologous strains of CHIKV challenge. Vaccine development
of the Asian genotype was carried through to an initial human trial
in which signiﬁcant levels of neutralizing antibody were detected
in all subjects.70
An updated version of an inactivated virus vaccine candidate is
being developed following the recent CHIKV outbreak in India. The
vaccine was derived from a novel, Indian isolate of the ECSA
genotype, which was Vero cell-adapted and formalin-inactivated
and used in combination with aluminum hydroxide as an adjuvant.
In a mouse models system, results from ELISA, a plaque reduction
neutralization test, and a cytokine proﬁle of isolated splenocytes,
indicated the induction of both humoral and cellular immune
responses after subcutaneous injection.71
Perhaps the most well studied CHIKV vaccine candidate is a live
attenuated virus vaccine (LAV) developed by the US Army using a
Thai isolate, CHIKV strain 15561, which underwent 18 plaque-to-
plaque passages in the human lung ﬁbroblast MRC-5 cell line. The
resulting CHIK 181/clone 25 (181/25) candidate exhibited an
attenuated phenotype both in vitro and in vivo. The vaccine
candidate was able to induce neutralizing antibodies, protect mice
against lethal challenge, and immunized Rhesus monkeys showed
no viremia following challenge.72 The lyophilized supernatant
from CHIK 181/25-infected MRC-5 cells, designated as TSI-GSD-
218, was shown to be safe and immunogenic in a phase I trial.73 In a
phase II trial, 95% of the 59 volunteers who received a single
subcutaneous dose of the TSI-GSD-218 vaccine elicited neutraliz-
ing antibodies, and 85% remained seropositive 1 year after
immunization; while transient arthralgia was experienced by 8%of the vaccinees, adverse reactions were generally similar in nature
and extent to those experienced by the placebo group.74
As CHIK 181/25 is a live, albeit an attenuated virus, safety
concerns about the possibility of natural transmission by a
mosquito vector must always be considered, and indeed, in a
series of experiments, Turell and Malinoski75 showed that the CHIK
181/25 virus was able to replicate in female Aedes mosquitoes
after intrathoracic inoculation, and was transmissible. Neverthe-
less, there was no evidence of reversion of the vaccine candidate
strain to a more virulent phenotype upon replication in mosqui-
toes, and given the low viremia this vaccine produced in vivo, it is
unlikely that mosquitoes would become infected via feeding on a
vaccinee.75
The incidence of some adverse events in the TSI-GSD-218
clinical trial prompted another group of researchers to pursue an
alternative LAV candidate strategy. Chimeric alphavirus vaccine
candidates with backbones of either the attenuated Venezuelan
equine encephalitis vaccine strain TC-83 or a naturally attenuated
strain of eastern equine encephalitis virus or an attenuated Sindbis
virus were constructed to contain the structural proteins of a
CHIKV strain isolated during the La Re´union outbreak.76 In addition
to inducing a robust humoral immune response, the chimeras did
not trigger reactogenicity in immunized adult mice as indicated by
the lack of signs of neurological disease, febrile responses, or
growth delays. In newborn mice, the chimeric alphavirus vaccine
candidates showed better attenuation in terms of lower titers and a
shorter duration of viremia as compared to the CHIK 181/25
vaccine candidate, and unlike mice immunized with CHIKV wild-
type or CHIK 181/25, there was no detectable viral replication in
the femoro-tibial joints or in the brains of mice immunized with
the chimeras.76 Taken together, the chimeric alphaviruses appear
to be promising CHIKV vaccine candidates, yet further studies to
determine the most appropriate chimeric construct and the
vaccination regimen in another animal model are essential.
There will always be some risk concerns, including under-
attenuation and pathogenic reversion related to LAVs, whether
naturally attenuated or chimeric, and similarly, inactivated virus
vaccines are of concern, particularly in immunocompromised
individuals, with regards to incomplete inactivation. To address
these issues, several alternate approaches to CHIKV vaccine
development are under investigation.
In the ﬁrst of these, novel consensus-based DNA vaccines for
CHIKV are being developed. The vaccine candidates were designed
based upon the consensus sequences of the E1, E2, and C proteins
from 21 CHIKV isolates collected between 1952 and 2006. In
addition, codon and RNA optimization were conducted, a Kozak
sequence was added, and the signal peptide substituted with an
immunoglobulin E leader sequence to improve vaccine efﬁcacy.
After three intramuscular immunizations with each plasmid DNA
vaccine candidate, mice showed signiﬁcant levels of anti-E1-
speciﬁc, anti-E2-speciﬁc, or anti-C-speciﬁc IgG antibodies and
interferon-gamma (IFN-g) production, suggesting a strong hu-
moral as well as cellular immune response.77,78 More recently, a
single plasmid that encodes the CHIKV envelope glycoproteins (E3,
E2, and E1) was constructed using the same strategy. This new DNA
vaccine induced a better immune response than the original
constructs that expressed the CHIKV structural proteins individu-
ally. In addition, this DNA vaccine candidate was able to protect
mice from challenge with a recent clinical isolate of CHIKV. An
initial study in rhesus macaques showed the induction of
hemagglutination inhibition antibodies, virus neutralizing anti-
bodies, and IFN-g.79
As an alternative to DNA vaccines in avoiding the problem
associated with whole virus (inactivated or live attenuated)
vaccines, virus-like particles (VLPs) are also being explored, as
they are known to be safe while inducing a better immune
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alphavirus VLPs were generated by expressing the structural
proteins (C-E3-E2-6K-E1) from an old West African (strain 37997)
lineage of CHIKV in 293T human kidney cells.80 In animal model
studies, serum from VLP 37997 vaccinated mice and monkeys
showed comparable levels of neutralization against the homolo-
gous strain 37997 and a heterologous strain from the recent
outbreak of the ECSA lineage (LR2006 OPY-1). Furthermore,
passive transfer of puriﬁed IgG from an immunized monkey was
able to completely protect type I interferon-defective mice from
lethal challenge with LR2006 OPY-1, without detectable vire-
mia.14,80 In a similar manner, IgG isolated from CHIKV conva-
lescent patients has been shown to prevent and cure CHIKV
infection in mice,81 suggesting that passive immunotherapy may
be useful to control or treat CHIKV infection, and two human
monoclonal antibodies with strong and speciﬁc neutralization
activity have recently been described.82
Despite the potential of CHIKV vaccine candidates in the 1980s
(such as the US Army vaccine candidate), the worldwide lull in the
incidence of cases of chikungunya fever appears to have removed
the driving force for bringing these products to commercial
distribution, and to have stiﬂed further CHIKV vaccine develop-
ment. The massive resurgence of CHIKV around the Indian Ocean
and elsewhere from 2005 onwards, as well as the introduction of
CHIKV to Europe, therefore took place in the absence of a viable
preventive vaccine. Clearly however, the outbreak has provided
new impetus to the development of a safe, cheap, and effective
CHIKV vaccine. While a number of signiﬁcant questions remain to
be addressed related to vaccine validation, such as the most
appropriate animal models (species, age, immune status), the dose
and route of immunization, the potential interference from
multiple vaccinations against different viruses, and last but not
least, the practical cost of the vaccine, since most of the epidemic
geographical regions belong to the developing countries, there is
real hope that a vaccine to prevent this disease will not be too long
in arriving.
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